Siddhant Kabra, a member of the Promoter Group of Eiko Lifesciences Limited, has acquired 47,000 equity shares of the company, representing 0.33% of the total issued and subscribed share capital. This acquisition has resulted in an increase in Siddhant Kabra’s aggregate holding in the company to 5,63,650 equity shares, accounting for 4.06% of the total shareholding.

The disclosure was made under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure was submitted to both the Bombay Stock Exchange (BSE Limited) and the Compliance Officer of Eiko Lifesciences Limited on March 17, 2025.

Details of the Acquisition

The acquisition was carried out through an open market purchase on March 17, 2025. Siddhant Kabra’s prior holding consisted of 5,16,650 equity shares, representing 3.72% of the total voting capital of the company. Following the acquisition of an additional 47,000 shares, his holding increased to 5,63,650 shares, raising his stake to 4.06% of the total equity capital.

Breakdown of Acquisition Details:

• Number of Shares Acquired: 47,000 shares
• Percentage of Total Equity: 0.33%
• Mode of Acquisition: Open market purchase
• Date of Acquisition: March 17, 2025
• Total Holding Post-Acquisition: 5,63,650 shares (4.06%)

Disclosure as per SEBI Regulations

As per the requirements of Regulation 29(1) of SEBI (SAST) Regulations, 2011, an acquirer is mandated to disclose any acquisition or sale of shares that results in a change of 2% or more of the shareholding or voting rights of the target company. Although the acquisition of 47,000 shares by Siddhant Kabra represents a relatively small percentage of 0.33%, the disclosure was made to ensure regulatory compliance and transparency in promoter group transactions.

Pre and Post-Acquisition Holding Summary

• Pre-Acquisition Holding:

  • Number of Shares: 5,16,650
  • Percentage of Total Voting Capital: 3.72%

• Shares Acquired:

  • Number of Shares: 47,000
  • Percentage of Total Voting Capital: 0.33%

• Post-Acquisition Holding:

  • Number of Shares: 5,63,650
  • Percentage of Total Voting Capital: 4.06%

Company Overview and Share Capital

Eiko Lifesciences Limited is a listed company on the Bombay Stock Exchange (BSE) with a total equity capital comprising 1,38,60,445 equity shares of ₹10/- each, amounting to a total voting capital of ₹13,86,04,450. The company is engaged in the pharmaceutical and life sciences industry, with a focus on developing innovative solutions for the healthcare sector.

Stock Exchange and Compliance Details

• Name of Stock Exchange: Bombay Stock Exchange (BSE)
• Scrip Code: 540204
• Compliance Department Address:
  • BSE Limited: P J Towers, Dalal Street, Fort, Mumbai – 400001.
  • Eiko Lifesciences Limited: 604, Centrum, Opp TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane – 400604.

Mode and Impact of Acquisition

The open market acquisition by Siddhant Kabra reflects a strategic increase in promoter group holding. It indicates the promoter’s continued confidence in the company’s future growth and potential. By acquiring additional shares, the promoter group has reinforced its commitment to maintaining control and influencing the company’s growth trajectory.

Regulatory Compliance and Filing

The acquisition details were duly reported to the Bombay Stock Exchange (BSE Limited) and the Compliance Officer of Eiko Lifesciences Limited on March 17, 2025. As per SEBI’s guidelines, the disclosure was submitted in the prescribed format to ensure compliance with the regulatory framework governing substantial acquisition of shares and takeovers.

SEBI Regulations Overview

The disclosure was made pursuant to Regulation 29(1) of SEBI (SAST) Regulations, 2011, which requires that any acquisition resulting in changes to the shareholding pattern be reported to the stock exchange and the company. This regulation aims to ensure transparency and accountability in the acquisition process, preventing any adverse impact on minority shareholders.

Conclusion: Strengthening Promoter Control

The acquisition of 47,000 shares by Siddhant Kabra underlines the promoter group’s confidence in the company’s growth potential and its intent to strengthen its stake in the company. With a post-acquisition holding of 4.06% of the total voting capital, the promoter group has enhanced its influence over the company’s decision-making process. The timely disclosure in line with SEBI regulations ensures that all stakeholders remain informed about the changes in the shareholding structure of Eiko Lifesciences Limited.

The Upcoming IPOs in this week and coming weeks are Arisinfra Solutions Limited, Grand Continental Hotels, Rapid Fleet Management Services.

The Current active IPO are Paradeep Parivahan, Divine Hira Jewellers.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst